Combined therapeutic efficacy of 188Re‑liposomes and sorafenib in an experimental colorectal cancer liver metastasis model by intrasplenic injection of C26‑luc murine colon cancer cells

Chang,Ya‑Jen; Hsu,Wei‑Hsin; Chang,Chih‑Hsien; Lan,Keng‑Li; Ting,Gann; Lee,Te‑Wei

doi:10.3892/mco.2014.246

Combined therapeutic efficacy of 188Re‑liposomes and sorafenib in an experimental colorectal cancer liver metastasis model by intrasplenic injection of C26‑luc murine colon cancer cells

Authors:
- Ya‑Jen Chang
- Wei‑Hsin Hsu
- Chih‑Hsien Chang
- Keng‑Li Lan
- Gann Ting
- Te‑Wei Lee
View Affiliations

Affiliations: Institute of Nuclear Energy Research, Lungtan, Taoyuan, Taiwan, R.O.C., Cancer Center, Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C., National Health Research Institutes, Taipei, Taiwan, R.O.C.
Published online on: January 20, 2014 https://doi.org/10.3892/mco.2014.246
Pages: 380-384

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Rhenium‑188 (188Re) displays abundant intermediate energy β emission and possesses a physical half‑life of 16.9 h. Sorafenib is an orally available multikinase inhibitor that targets Raf kinases and vascular endothelial growth factor receptors (VEGFRs). Sorafenib has demonstrated preclinical and clinical activity against several types of tumors, such as renal cell and colorectal carcinoma. In this study, we investigated the efficacy of radiotherapeutics of 188Re‑liposomes combined with sorafenib in a C26‑luc metastatic colorectal liver tumour mouse model. Liver metastases were established by intrasplenic injection of C26‑luc murine colon cancer cells. Based on the results of the toxicity assessment, an administration dose of 80% the maximum tolerated dose was selected. 188Re‑liposomes were administered on day 1, when metastases of several hundred micrometers in diameter were observed. In the combination therapy group, 10 mg̸kg sorafenib (co‑developed and co‑marketed by Bayer and Onyx Pharmaceuticals as Nexavar) was administered every other day for 1 week and the survival of mice was assessed. The tumor growth was more significantly inhibited in the 188Re‑liposome plus sorafenib group compared with the 188Re‑liposome alone, sorafenib alone and untreated normal saline groups (P=0.0000). Furthermore, 188Re‑liposomes combined with sorafenib achieved higher survival rates compared with the 188Re‑liposome alone, sorafenib alone and untreated normal saline groups (P=0.0000). These results support the use of combined radio‑chemotherapy with 188Re‑liposomes plus sorafenib as a viable treatment option in the adjuvant setting for liver metastases of colorectal cancer.

View Figures

View References

1.	Reissfelder C, Timke C, Schmitz-Winnenthal H, et al: A randomized controlled trial to investigate the influence of low dose radiotherapy on immune stimulatory effects in liver metastases of colorectal cancer. BMC Cancer. 11:4192011. View Article : Google Scholar
2.	Reissfelder C, Rahbari NN, Koch M, Ulrich A, Pfeilschifter I, Waltert A, Muller SA, Schemmer P, Buchler MW and Weitz J: Validation of prognostic scoring systems for patients undergoing resection of colorectal cancer liver metastases. Ann Surg Oncol. 16:3279–3288. 2009. View Article : Google Scholar : PubMed/NCBI
3.	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
4.	Cummings LC, Payes JD and Cooper GS: Survival after hepatic resection in metastatic colorectal cancer: a population-based study. Cancer. 109:718–726. 2007. View Article : Google Scholar : PubMed/NCBI
5.	Vavrova J and Rezacova M: The importance of senescence in ionizing radiation-induced tumour suppression. Folia Biol. 57:41–46. 2011.PubMed/NCBI
6.	Bakkenist CJ and Kastan MB: DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature. 421:499–506. 2003. View Article : Google Scholar : PubMed/NCBI
7.	Jeggo PA, Geuting V and Lobrich M: The role of homologous recombination in radiation-induced double-strand break repair. Radiother Oncol. 101:7–12. 2011. View Article : Google Scholar : PubMed/NCBI
8.	Lobrich M and Jeggo PA: The impact of a negligent G2/M checkpoint on genomic instability and cancer induction. Nat Rev Cancer. 7:861–869. 2007. View Article : Google Scholar : PubMed/NCBI
9.	Jeggo PA and Löbrich M: DNA double-strand breaks: their cellular and clinical impact? Oncogene. 26:7717–7719. 2007. View Article : Google Scholar : PubMed/NCBI
10.	Davis ME, Chen ZG and Shin DM: Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 7:771–782. 2008. View Article : Google Scholar : PubMed/NCBI
11.	Cho K, Wang X, Nie S, Chen ZG and Shin DM: Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res. 14:1310–1316. 2008. View Article : Google Scholar : PubMed/NCBI
12.	Wolpin BM, Meyerhardt JA, Mamon HJ and Mayer RJ: Adjuvant treatment of colorectal cancer. CA Cancer J Clin. 57:168–185. 2007. View Article : Google Scholar
13.	Brannon-Peppas L and Blanchette JO: Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev. 56:1649–1659. 2004. View Article : Google Scholar : PubMed/NCBI
14.	Chang YJ, Chang CH, Chang TJ, Yu CY, Chen LC, Jan ML, Luo TY, Lee TW and Ting G: Biodistribution, pharmacokinetics and microSPECT/CT imaging of ¹⁸⁸Re-bMEDA-liposome in a C26 murine colon carcinoma solid tumor animal model. Anticancer Res. 27:2217–2225. 2007.PubMed/NCBI
15.	Chen LC, Chang CH, Yu CY, Chang YJ, Hsu WC, Ho CL, Yeh CH, Luo TY, Lee TW and Ting G: Biodistribution, pharmacokinetics and imaging of ¹⁸⁸Re-BMEDA-labeled pegylated liposomes after intraperitoneal injection in a C26 colon carcinoma ascites mouse model. Nucl Med Biol. 34:415–423. 2007.
16.	Ibrahim N, Yu Y, Walsh WR and Yang JL: Molecular targeted therapies for cancer: Sorafenib mono-therapy and its combination with other therapies (Review). Oncol Rep. 27:1303–1311. 2012.PubMed/NCBI
17.	Dal Lago L, D′Hondt V and Awada A: Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors. Oncologist. 13:845–858. 2008.PubMed/NCBI
18.	Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM and Lynch M: Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 7:3129–3140. 2008. View Article : Google Scholar : PubMed/NCBI
19.	Wilhelm SM, Carter C, Tang L, et al: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64:7099–7109. 2004. View Article : Google Scholar : PubMed/NCBI
20.	Escudier B, Eisen T, Stadler WM, et al TARGET Study Group: Sorafenib in advanced clear-cell renal-cell carcinoma. New Engl J Med. 356:125–134. 2007. View Article : Google Scholar : PubMed/NCBI
21.	Llovet JM, Ricci S, Mazzaferro V, et al SHARP Investigators Study Group: Sorafenib in advanced hepatocellular carcinoma. New Engl J Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
22.	Suen AW, Galoforo S, Marples B, McGonagle M, Downing L, Martinez AA, Robertson JM and Wilson GD: Sorafenib and radiation: a promising combination in colorectal cancer. Int J Radiat Oncol Biol Phys. 78:213–220. 2010. View Article : Google Scholar : PubMed/NCBI
23.	Kim YB, Jeung HC, Jeong I, Lee K, Rha SY, Chung HC and Kim GE: Mechanism of enhancement of radiation-induced cytotoxicity by sorafenib in colorectal cancer. J Radiat Res. 54:52–60. 2013. View Article : Google Scholar : PubMed/NCBI
24.	Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S and Bardelli A: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 26:5705–5712. 2008.
25.	Ratain MJ, Eisen T, Stadler WM, et al: Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 24:2505–2512. 2006. View Article : Google Scholar
26.	Wehler TC, Hamdi S, Maderer A, et al: Single-agent therapy with sorafenib or 5-FU is equally effective in human colorectal cancer xenograft - no benefit of combination therapy. Int J Colorect Dis. 28:385–398. 2013. View Article : Google Scholar : PubMed/NCBI
27.	Kuo YC, Lin WC, Chiang IT, Chang YF, Chen CW, Su SH, Chen CL and Hwang JJ: Sorafenib sensitizes human colorectal carcinoma to radiation via suppression of NF-kappaB expression in vitro and in vivo. Biomed Pharmacother. 66:12–20. 2012. View Article : Google Scholar : PubMed/NCBI
28.	Martinelli E, Troiani T, Morgillo F, et al: Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells. Clin Cancer Res. 16:4990–5001. 2010. View Article : Google Scholar : PubMed/NCBI
29.	Galal KM, Khaled Z and Mourad AM: Role of cetuximab and sorafenib in treatment of metastatic colorectal cancer. Indian J Cancer. 48:47–54. 2011. View Article : Google Scholar : PubMed/NCBI
30.	Plastaras JP, Kim SH, Liu YY, et al: Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Res. 67:9443–9454. 2007. View Article : Google Scholar : PubMed/NCBI
31.	Amundson SA, Bittner M and Fornace AJ Jr: Functional genomics as a window on radiation stress signaling. Oncogene. 22:5828–5833. 2003. View Article : Google Scholar : PubMed/NCBI
32.	Abraham RT: Checkpoint signaling: epigenetic events sound the DNA strand-breaks alarm to the ATM protein kinase. Bioessays. 25:627–630. 2003. View Article : Google Scholar : PubMed/NCBI
33.	Valerie K, Yacoub A, Hagan MP, Curiel DT, Fisher PB, Grant S and Dent P: Radiation-induced cell signaling: inside-out and outside-in. Mol Cancer Ther. 6:789–801. 2007. View Article : Google Scholar : PubMed/NCBI
34.	Dent P, Yacoub A, Fisher PB, Hagan MP and Grant S: MAPK pathways in radiation responses. Oncogene. 22:5885–5896. 2003. View Article : Google Scholar : PubMed/NCBI
35.	Deshpande A, Sicinski P and Hinds PW: Cyclins and cdks in development and cancer: a perspective. Oncogene. 24:2909–2915. 2005. View Article : Google Scholar : PubMed/NCBI
36.	Jirawatnotai S, Hu Y, Michowski W, et al: A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers. Nature. 474:230–234. 2011. View Article : Google Scholar : PubMed/NCBI